TransCode Therapeutics (RNAZ – Research Report) received a Buy rating and a $6.00 price target from H.C. Wainwright analyst Emily Bodnar today. The company’s shares opened today at $0.70.
Bodnar covers the Healthcare sector, focusing on stocks such as SQZ Biotechnologies, Olema Pharmaceuticals, and TransCode Therapeutics. According to TipRanks, Bodnar has an average return of -28.7% and a 18.03% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for TransCode Therapeutics with a $6.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $3.13 and a one-year low of $0.28. Currently, TransCode Therapeutics has an average volume of 3.2M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.
Read More on RNAZ:
- TransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial
- TransCode Therapeutics Announces Withdrawal of Registration Statement
- Transcode Therapeutics announces eIND submission to U.S. FDA
- TransCode Therapeutics Reports Third Quarter 2022 Results; Provides Business Update
- TransCode Therapeutics to Present at Sidoti Virtual Investor Conference
